| Literature DB >> 34015720 |
Monic Andrew1, Gurunathan Jayaraman2.
Abstract
The viral infection caused by SARS-CoV-2 has increased the mortality rate and engaged several adverse effects on the affected individuals. Currently available antiviral drugs have found to be unsuccessful in the treatment of COVID-19 patients. The demand for efficient antiviral drugs has created a huge burden on physicians and health workers. Plasma therapy seems to be less accomplishable due to insufficient donors to donate plasma and low recovery rate from viral infection. Repurposing of antivirals has been evolved as a suitable strategy in the current treatment and preventive measures. The concept of drug repurposing represents new experimental approaches for effective therapeutic benefits. Besides, SARS-CoV-2 exhibits several complications such as lung damage, blood clot formation, respiratory illness and organ failures in most of the patients. Based on the accumulation of data, sulfated marine polysaccharides have exerted successful inhibition of virus entry, attachment and replication with known or unknown possible mechanisms against deadly animal and human viruses so far. Since the virus entry into the host cells is the key process, the prevention of such entry mechanism makes any antiviral strategy effective. Enveloped viruses are more sensitive to polyanions than non-enveloped viruses. Besides, the viral infection caused by RNA virus types embarks severe oxidative stress in the human body that leads to malfunction of tissues and organs. In this context, polysaccharides play a very significant role in providing shielding effect against the virus due to their polyanionic rich features and a molecular weight that hinders their reactive surface glycoproteins. Significantly the functional groups especially sulfate, sulfate pattern and addition, uronic acids, monosaccharides, glycosidic linkage and high molecular weight have greater influence in the antiviral activity. Moreover, they are very good antioxidants that can reduce the free radical generation and provokes intracellular antioxidant enzymes. Additionally, polysaccharides enable a host-virus immune response, activate phagocytosis and stimulate interferon systems. Therefore, polysaccharides can be used as candidate drugs, adjuvants in vaccines or combination with other antivirals, antioxidants and immune-activating nutritional supplements and antiviral materials in healthcare products to prevent SARS-CoV-2 infection.Entities:
Keywords: Antivirals; COVID-19; Drug repurposing; Immunomodulators; SARS-CoV-2; Sulfated polysaccharide
Mesh:
Substances:
Year: 2021 PMID: 34015720 PMCID: PMC8091805 DOI: 10.1016/j.carres.2021.108326
Source DB: PubMed Journal: Carbohydr Res ISSN: 0008-6215 Impact factor: 2.975
Fig. 1Basic structure of SARS-CoV-2: The structure contains four main proteins that encapsulates the viral genomic RNA: the envelope protein (E), membrane glycoprotein (M), spike glycoprotein (S) and nucleocapsid protein (N) [216] (Section 2).
Fig. 2The impact of SARS-CoV-2 infection on human organs including major symptoms (Section 2).
Fig. 3Schematic representation of major essential factors influencing the antiviral activity of sulfated polysaccharides, Lambda-carrageenan [217,218], Fucoidan [219,220], Ulvanobiuronicacid A3s [221,222] (Section 4).
Fig. 4(A) General schematic representation of virus attachment and entry into the host cell- (i) Initial attachment of virus to cell surface receptors takes place through binding process [223,224]. (B) Mode of antiviral action of sulfated polysaccharides (Lambda-carrageenan, Fucoidan, Ulvanobiuronicacid A3s) (ii) The polysaccharide involving in the prevention of virus attachment to host cells by providing (iii) shielding effect that fails the (iv) virus receptor binding activity (Table 1). (Section5.1).
Sulfated polysaccharide from different sources and their mode of virus inhibition.
| S.No | Name of the Polysaccharide and Organism | Sources | Virus Inhibition mechanism | Type of Virus | References |
|---|---|---|---|---|---|
| Carrageenan | Marine red alga | Inhibition of propagation | Herpes simplex virus type 1 (HSV-1) and Rift valley fever virus (RVFV) | [ | |
| Marine macroalga | Inhibition of viral entry | Avian Influenza Virus (H9N2 subtype) | [ | ||
| Ascophyllan | Marine brown algae | Inhibition of early step of viral infection | Human immunodeficiency virus (HIV-1) and vesicular stomatitis virus (VSV)-G-pseudotyped HIV-1 | [ | |
| Sulfated rhamnan | Marine green alga | Inhibition of invasion, replication and reduction of viral titers | Enterovirus 71 (EV71) | [ | |
| Brown macroalga | Not specified | Herpes simplex virus HSV-1 strain F | [ | ||
| Marine Sponge | Prevention of viral attachment and entry | Human immunodeficiency virus HIV-1 | [ | ||
| Marine brown alga | Inhibition of virus attachment | Herpes simplex virus HSV-1 | [ | ||
| Fucoidan and alginate | Brown and red macroalga | Inhibition of virus penetration and reduction of syncytia formation | Measles virus | [ | |
| Marine microalga | Inhibition of virus entry | Vaccinia virus and Vesicular stomatitis virus | [ | ||
| Glucuronorhamnan | Green macroalga | Prevention of adsorption and blocking of the virus life cycle | Enterovirus 71 (EV71) | [ | |
| Red, brown and green macroalgae | Prevention of adsorption and internalization | Dengue virus (DENV) | [ | ||
| Fucoidan | Brown alga | Inhibition of syncytia formation and cell-to-cell spread of NDV | Newcastle Disease Virus (NDV) | [ | |
| P-KG03 | Marine red microalga | Prevention of viral adsorption and internalization | Influenza type A virus | [ | |
| Marine red algae | Inhibition of replication | HIV and HSV-1 | [ | ||
| Fucosylated chondroitin sulfate (FuCS-1) | Sea cucumber | Blocking entry and replication | HIV strains | [ | |
| Fucans | Brown macroalgae | Inhibition of adsorption and blocking fusion events | Influenza A/PR/8/34 virus | [ | |
| Ulvan | Green alga | Inhibition of adsorption and penetration | HSV | [ | |
| Fucoidan | Marine brown algae | Reverse transcriptase inhibition activity | HIV-1 | [ | |
| Xylomannan sulfate | Red macroalga | Inhibition of replication and direct virucidal activity | HSV-1 | [ | |
| Ulvan | Marine green alga | Inhibition of infection and replication | Vesicular stomatitis virus (VSV) | [ | |
| Calcium spirulan | Marine blue-green alga | Inhibition of virus entry | HSV-1 | [ | |
| Nostoflan | Blue-green alga | Inhibition of virus binding to host cells | HSV-1 and HSV-2, human cytomegalovirus, and influenza A virus | [ | |
| A1 and A2 | Marine red microalga | Not specified | HIV-1, influenza virus types A and B, respiratory syncytial virus types A and B | [ | |
| Mucopolysaccharide (OKU40) | Marine algae and marine bacteria | Inhibition of virus-cell fusion and viral adsorption. | HIV-1 and HIV-2 | [ | |
| Fucoidan | Marine brown macroalgae | Inhibition of propagation and proliferation | HIV | [ | |
| Polyguluronate sulfate | Marine brown algae | Inhibition of protein expression and transcription | Hepatitis B virus | [ | |
| Sulfated chitosan 36S | Artificially synthesized (fungi and shrimps) | Inhibition of viral entry and adsorption | Human papillomavirus | [ | |
| Iota-Carrageenan | Red macroalga | Prevention of virus binding, entry and replication | Human rhinovirus (HRV) | [ | |
| Agarans and carrageenan | Macroalgae | Inhibition of virus adsorption and early viral replication | HSV-1 and HSV-2 | [ | |
| λ-carrageenan | Red Macroalgae | Inhibition of virus entry during both primary and antibody-dependent infection | DENV serotypes | [ |
Fig. 5(A) General schematic representation of the virus lifecycle post attachment into the host cell- (i) Virus adsorption and internalization after the attachment to the receptor (ii) initiation of fusion event by the virus with plasma membrane of the host cell via endocytosis and its transportation/translocation to the cytoplasm leading to (iii) virus penetration [225,226]. (B) Mode of antiviral action of sulfated polysaccharides (Lambda-carrageenan, Fucoidan, Ulvanobiuronicacid A3s) (iv) inhibition of virus adsorption and internalization (v) inhibition of membrane fusion (plasma membrane) and (vii) inhibition of virus penetration by the interaction of polysaccharides that confers (vi) masking effect, complex formation and destabilizing of fusion peptides (Table 1). (Section 5.2).
Fig. 6(A) General schematic representation of later stages of virus lifecycle- (i) partial uncoating of virus particles takes place in the cytosol/nucleus. Initiation of (ii) transcription (iii) translation and (iv) replication resulting in the (v) biosynthesis and assembly of new virions (vi) virus release through exocytosis and (vii) budding of progeny virus [[227], [228], [229]]. (B) Mode of antiviral action of sulfated polysaccharides (Lambda-carrageenan, Fucoidan, Ulvanobiuronicacid A3s) (viii) inhibition of endosomal membrane fusion and virus uncoating (ix) inhibition of RNA genome and (x) protein synthesis. (xi) inhibition and deactivation of enzymes responsible for replication by the interaction of polysaccharides (Table 1). (Section 5.3).
Fig. 7Schematic representation of sulfated polysaccharides (Lambda-carrageenan, Fucoidan, Ulvanobiuronicacid A3s) influencing various modes of immune activation/modulation (Section 6).
Fig. 8Schematic representation of sulfated polysaccharides (Lambda-carrageenan, Fucoidan, Ulvanobiuronicacid A3s) influencing their antioxidant activity (Section 7).
Fig. 9Schematic representation of sulfated polysaccharides (Lambda-carrageenan, Fucoidan, Ulvanobiuronicacid A3s) influencing their antithrombotic and anticoagulant activity (Section 8).